Tranexamic acid evidence and controversies: An illustrated review

Tranexamic acid (TXA) is an antifibrinolytic agent commonly used for the treatment or prevention of bleeding. Indications for TXA are diverse, including heavy menstrual bleeding, trauma, postpartum hemorrhage, traumatic brain injury, and surgical site bleeding. Despite decades of use and a robust bo...

Full description

Saved in:
Bibliographic Details
Published inResearch and practice in thrombosis and haemostasis Vol. 5; no. 5; pp. e12546 - n/a
Main Authors Relke, Nicole, Chornenki, Nicholas L.J., Sholzberg, Michelle
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.07.2021
Elsevier Limited
John Wiley and Sons Inc
Elsevier
Subjects
Antifibrinolytic agents
blood coagulation
contraceptive agents
Illustrated Review
Illustrated Reviews
thrombosis
tranexamic acid
antifibrinolytic agents
contraceptive agents
thrombosis
blood coagulation
tranexamic acid
Online AccessGet full text

Cover

More Information
Summary:Tranexamic acid (TXA) is an antifibrinolytic agent commonly used for the treatment or prevention of bleeding. Indications for TXA are diverse, including heavy menstrual bleeding, trauma, postpartum hemorrhage, traumatic brain injury, and surgical site bleeding. Despite decades of use and a robust body of evidence, hesitancy using TXA persists in many clinical settings. This illustrated review describes the history, pharmacology, and practical considerations of TXA use. We also describe the major landmark randomized controlled trials of TXA and their implications. Finally, we review the evidence around common controversies surrounding TXA such as the risk of thrombosis, prescription along with combined hormonal contraceptives, and use in patients with gross hematuria.
Bibliography:Handling Editor: Alisa Wolberg.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2475-0379
2475-0379
DOI:10.1002/rth2.12546